# Efficacy and Safety of ATB-346 Versus Placebo in Osteoarthritis Patients

> **NCT03978208** · PHASE2 · COMPLETED · sponsor: **Antibe Therapeutics Inc.** · enrollment: 381 (actual)

## Conditions studied

- Osteoarthritis

## Interventions

- **DRUG:** ATB-346 low dose
- **OTHER:** Placebo
- **DRUG:** ATB-346 mid-dose
- **DRUG:** ATB-346 standard dose

## Key facts

- **NCT ID:** NCT03978208
- **Lead sponsor:** Antibe Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-29
- **Primary completion:** 2019-12-29
- **Final completion:** 2019-12-29
- **Target enrollment:** 381 (ACTUAL)
- **Last updated:** 2022-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03978208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03978208, "Efficacy and Safety of ATB-346 Versus Placebo in Osteoarthritis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03978208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*